mRNA
Moderna starts human trials of an mRNA-based flu shot
Moderna gave its mRNA-based seasonal flu vaccine to the first set of volunteers in a clinical trial, the pharmaceutical company announced today. The start of the trial marks the next stage of the company’s work on this type of vaccine technology after the overwhelming success of its COVID-19 vaccine, which was built using the same strategy. Before the COVID-19 pandemic, mRNA vaccines were still largely experimental, even as they were heralded as the future of vaccine development. People who get an mRNA vaccine are injected with tiny snippets of genetic material from the target virus. Their cells use that genetic information to build bits of the virus, which the body’s immune system learns to fight against. The high efficacy of the mRNA COVID-19 vaccines made by Moderna and Pfizer / BioNTec...
Ramaphosa, Macron Announce “Landmark” Plan to Produce mRNA Vaccines in South Africa
French President Emmanuel Macron and South African President Cyril Ramaphosa. Image sourced from The Sowetan. /* custom css */ .tdi_4_eed.td-a-rec-img{ text-align: left; }.tdi_4_eed.td-a-rec-img img{ margin: 0 auto 0 0; } South Africa is set to build a new hub for manufacturing COVID-19 vaccines, announces President Cyril Ramaphosa. Ramaphosa addressed a joint press conference with French President Emmanuel Macron on Monday. The conference was facilitated by the World Health Organisation (WHO). Macron, who referred to Ramaphosa as “my friend”, said that the partnership was the result of his state visit to South Africa at the end of last month. /* custom css */ .tdi_3_7dd.td-a-rec-img{ text-align: left; }.tdi_3_7dd.td-a-rec-img img{ margin: 0 auto 0 0; } The WHO issued a call for Expression...
Nigerian government lists conditions for states to access coronavirus vaccines
The Federal Government has listed conditions for states to meet before the Pfizer/BioNTech vaccine being expected wt the end of January would be released to them. The National Primary Health Care Development Agency (NPHCDA), during a webinar tagged “Sensitisation Meeting with Media Gatekeepers on COVID-19 Vaccine Introduction”, at the weekend, said no vaccine will be release to states until facilities such as cold chains are in place. According to Director, Logistics and Health Commodities, NHPCDA, Kubura Daradara, the vaccine must be administered within five days of receipt for it to remain potent, and only the states that show commitment would receive the doses when available. She added that the 100,000 doses would be administered to 50,000 people, because each person has to take a secon...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
